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Abstract  
 
This paper focuses on the challenges of meeting agency requirements as it pertains to 
the application of human factors in the medical device development process.  Individual 
case studies of the design and development process for 18 medical device 
manufacturers located in the US and EU were analyzed and compared using a multiple 
case study design.  The results indicate that there are four main challenges in 
implementing international standards.  These include a lack of direct access to users for 
the purposes of device development; a lack of understanding by users with regards to 
the impact of their feedback on the development process; contract formalities limiting 
user exchanges; and the perceived attitudes of clinical users which impact participation 
in human factors studies.  The barriers presented in this research have the potential to 
be resolved but only with greater commitment by both medical device users and 
developers. 
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1 Introduction 
 
The design of medical devices starts with a need and a description of the concept or 
problem (Ogrodnick 2013).  In order for a new device to be used within the clinical 
environment, certain development procedures must be undertaken, such as a regulatory 
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plan and design optimization through verification/validation (Whitmore 2004; Zenios et al. 
2010; Ogrodnik 2013).  Furthermore, the integration of human factors in medical device 
design process is required to reduce risk and improve patient safety (FDA 2011; MHRA 
2016).   Additionally, design Control is a fundamental requirement to meet regulatory 
approval for international standards (FDA CDRH, 1997; Ogrodnick 2013).  It documents 
the history of development and ensures that the origins of any decision made during the 
development process are traceable.  In order to improve the ability of designers and 
auditors to ascertain the safety and efficacy of a product, the use of design controls has 
been adopted in order to specify the appropriate method for device review at several key 
stages (Gilman et al. 2009).   The framework of this model meets United States (US) 
Federal Regulation 820.30 for Design Control (Justiniano and Gopalaswamy 2003; 
Gilman et al. 2009; Panescu 2009).  For example, in determining user needs, 
ethnography and/or contextual inquiry is undertaken in order to write formative usability 
objectives that meet industry standards for the Association for the Advancement of 
Medical Instrumentation (AAMI) (AAMI, 2009)/American National Standards Institute 
(ANSI) Human Engineering Standard 75 and International Electrotechnical Commission 
(IEC) (IEC 62366: 2007/(R) 2013).  Wilcox (2012) explains the use of ethnographic 
research in medical device development in order to learn what actually takes place, as 
opposed to what people say takes place and then using that information to create 
devices that reduce error and improve productivity. This paper focuses on the 
challenges of meeting these agency requirements as it pertains to the application of 
human factors in the medical device development process in both the US and the 
European Union (EU).  This furthers the research of Vicent et al (2014), wherein barriers, 
such as communication breakdowns between users and design teams hindered 
integrating human factors in medical device design (Vincent et al. 2014).   For reference, 
the human factors standards applicable to medical device development are as follows: 
 
• IEC 62366-1:2015, Medical devices - Application of usability engineering to 
medical devices, published by the International Electrotechnical Commission. 
• IEC/TIR 62366-2:2016, Medical devices - Part 2: Guidance on the application of 
usability engineering to medical devices, published by the International 
Electrotechnical Commission. (Note: this standard was not published at the time 
of this study) 
• AAMI HE 75:2009, Human Factors Engineering – Design of Medical Devices, 
Section 9 – Usability Testing, published by the Association for the Advancement 
of Medical Instrumentation.  
• Medical Device Safety – Integrating Human Factors Engineering into Risk 
Management, June 18, 2000, available on the U.S. Food and Drug 
Administration’s website. 
• FDA's guidance document Applying Human Factors and Usability Engineering to 
Medical Devices, which addresses usability testing, issued on February 3, 2016, 
available on the U.S. Food and Drug Administration’s website. (Note: this 
guidance document was in draft during the time of this study) 
• ISO 14971:2007, Medical devices – Application of risk management to medical 
devices, published by the International Organization for Standardization. 
 
In the UK, the Competent Authority is Medicines & Healthcare products Regulatory 
Agency (MHRA).   The MRHA enforce the following regulations (MHRA 2016): 
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• The Medical Devices Regulations 2002 – SI 2002/618 (consolidated legislation) 
• The Medical Devices (Amendment) Regulations 2003 – SI 2003/1697 
• The Medical Devices (Amendment) Regulations 2007 – SI 2007/400 
• The Medical Devices (Amendment) Regulations 2008 – SI 2008/2936 
(transposes Directive 2007/47/EC into UK law (came into force March 2010))  
 
In 2016, The MHRA published draft guidance titled, “Human Factors and Usability 
Engineering – Guidance for Medical Devices Including Drug-device Combination 
Products” (MHRA 2016).  This document was not available at the time of the study; 
however, it provides an overview of the regulatory framework, the standards, process 
of usability engineering, simulation and post-market surveillance for the EU.  As 
evidenced by these international requirements, the application of human factors is 
critical to the device approval process. 
 
For clarity, the definition of who a user is in terms of a medical device can vary.  It 
can be a clinical provider, the patient, a parent or caregiver.  For example, Money et 
al. (2011) identify the user as any healthcare worker who may be required, either 
regularly or occasionally, to locate, examine or access blood vessels of patients or to 
assist with these tasks.  De Ana notes that careful analysis of all stakeholders is 
required to determine precisely who the user is for any device in development as it 
may be that through the use of the device the user may change from the provider to 
the patient or vice versa (De Ana et al. 2013).   
 
Kaye (AAMI 2013) comments on the fundamental challenge in medical device design 
as being, “…… the ability to identify and understand, particularly during design, possible use 
problems and the potential for harm associated with the use of medical devices.  Additionally, 
many system-use problems were context-specific, subtle, complex, and hard to identify.  
However, use related problems can be detected via formative testing and evaluation by users ” 
(AAMI 2013 p.9).  This can be seen as being indicative of the importance of early and 
direct user involvement before medical device development.  Observational research, 
such as contextual enquiry and usability testing, formalize user involvement in the 
design process at specific points, with all users being sensitive to device usability 
along with safety and efficacy (Wiklund and Wilcox 2005).  However, it is not possible 
to have every element of the design perfected to all user expectations in addition to 
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meeting the needs of safety, efficacy, and technical feasibility.  Fairbanks and Wears 
(2008) sum up the perception of users towards industry stating that device 
manufacturers should “…. presume there to be a design problem rather than a user problem 
and work from that starting point to find avenues for improvement…we cannot be satisfied 
with weak solutions that provide the illusion of action but will accomplish little or nothing, 
such as a new policy, exhortation, and training.” (Fairbanks and Wears, 2008 p. 520)  
In a study by Money et al. (2011), in-depth interviews were conducted with 
representatives from 11 medical device manufacturers.  They asked the 
manufacturers to identify whom they believe the intended users were; what role they 
had in the process; and what value (if, any) did they believe the users added.  They 
used thematic analysis to review transcripts and found there were perceived barriers 
to specific user groups in obtaining ethical approval, the speed at which such activity 
may be carried out and belief that there was no need to seek user input given the 
‘all-knowing’ nature of senior healthcare staff and clinical champions (ibid).  
Additionally, only one manufacturer claimed to regularly use formal user-centred 
design methods within the development process.  Hence, the only evidence of 
engagement with users was the formal methods that were mandatory and dictated 
to manufacturers by standards and purchasing agencies.  Money et al (2011) 
suggests the focus of IEC 62366 that device manufacturers should:   
• “Research to better understand the requirements of manufacturers, in terms 
what was required from human factors engineering methods in order to make 
their use more feasible and accessible in practice. 
• Provision of training on the use and benefits of employing formal human 
factors engineering methods at every stage of the medical device 
development process. 
• Healthcare providers should implement formal processes to ensure better 
communication and synergy between those making purchasing decisions and 
the actual users of the devices. 
• Provisions should be made within the ethical approval process that enables 
medical device manufacturers to engage more easily with users with minimal 
levels of bureaucracy while also ensuring that all research was conducted in 
an ethical manner that protects healthcare staff and patients” ( Money et al.. 
2011 p.11) 
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As a result of agency mandates and standards such as IEC 62366, users (customers) 
are most often involved in need determination, usability assessment and the 
development of surgical technique (Ogrodnick 2013).  Usability is considered as 
being important although not enough on its own to guarantee product success.  
Usability techniques can be used to improve a given situation but they do not reveal 
if a given situation is better or more enjoyable (Battarbee and Koshinen 2005).  
 
A realization that human error in operating a device can be a major cause of patient 
death or injury (Cafazzo & St-Cyr 2012)  identifies a need for collaboration 
throughout the design process rather than at formal mandated intervals.  As 
collaborative design techniques become more widely adopted, the role of the user 
has started to change.  In consumer product design, this calls for participation of 
users within the design process that involves users as co-creators (Sanders 2002).  It 
changes the perception of the role of users within the design process to nurture 
collective creativity, where users are active, competent participants (Binder et al. 
2008).  
 
Lin and Vicente (2001) comments that manufacturers have the capacity to enhance 
patient safety by putting a greater emphasis on the human factors engineering 
process in the design of devices.  This position is expanded by suggesting that 
government medical regulators may be able to enhance patient safety by putting an 
emphasis on human factors engineering design criteria when undertaking final 
product approval and regulatory decisions (ibid).  Specifically, the incorporation of 
human factors engineering methods within the medical device design and 
development process offer benefits that facilitate safer and more usable devices that 
are better suited to user needs (Money et al. 2011).  These methods include focus 
groups, interviews, usability testing and heuristic evaluation once a tangible device 
has been developed. As devices are released for use, hospital risk managers can 
enhance patient safety by adopting human factors engineering criteria during the 
evaluation of a new technology (Lin et al. 2001).  
 
Government mandates are one of the most powerful influences on medical device 
development.  They impose and recognize the rules or standards necessary to 
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market a device and have required post-market surveillance that is intended to 
identify issues as they occur.  Like the US ANSI/AAMI standards body, device 
manufacturers undertake the MRS on a voluntary basis. The National Health Services 
(NHS) in the UK uses the platform of standards in order to identify suppliers whose 
products have a measure of quality assurance and meet the requirements of the 
quality system standard (Crisp 1996).  Both the USA and the EU require the 
demonstration of a human factors engineering process throughout 
design/development and upon submission of a device dossier being assessed for 
device approval to market (Martin and Barnett 2012).  In all instances, the regulations 
and procedures required by the agencies describe what the documentation should 
contain but do not prescribe how the design/development process should actually 
be undertaken (Ogrodnick 2013). 
2 Methods 
 
Case studies are effective in the assessment of user engagement and in capturing 
design and development practices (Elf et al. 2007; Grocott et al. 2007; Taylor et al. 2007; 
Medina et al. 2012; Yin 2013).  Unlike the analysis of an individual case, this study 
compares practices from multiple cases that were selected based on the size of the 
company, device specialty, user group and use of industrial design.  Yin (2013) identifies 
case study research as being appropriate when the main research questions are ‘how’ 
or ‘why’ and where the researcher has little control over behavioral events.  Yin (2009) 
further describes case studies as coping with technically distinctive situations with more 
variables of interest rather than data points and the reliance on multiple sources of 
evidence.   As such, multiple case designs were considered as being more compelling, 
making the overall study more robust when replication logic was followed.   
Data analysis of case studies consists of using a standard set of variables with 
openness to new variables in order to form a foundation.  Once each case is understood, 
case level displays can be ‘stacked’ in a meta-matrix, thereby further condensing and 
permitting systematic comparison (Miles et al. 2013).  For this study, a graphic data 
display was used to develop a meta-matrix enabling the cross-referencing of variables. 
 
Figure 1 represents the template used to visualise each participating manufacturer.  
The graphic represents the specific requirements for each organisation in one graphic 
element and was used to enable analysis based on each specific requirement.  All 
manufacturers selected to participate in this study produced one or more of the 
following: Class II devices used in general hospital (GEN), critical care (CRIT), drug 
delivery (DELIV), surgery (SURG) or catheter based interventions (CATH).  The devices 
manufactured by participants included users who were physicians (DR), patients (PT), 
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technicians (TECH), nurses (NRS), and care providers (CARE) such as home healthcare 
providers.  Additionally, they ranged in size from small < 50 (SM), medium 51-149 
(MED) and large >150 (LG) and additional consideration was given to in-house 
industrial design (ID) or the lack thereof (NO ID).  A large number, represented by 
the X in Figure 1, provided a unique identifier for each company.    
 
Figure 1. Visual description used for each manufacturer 
A total of 18 Individual medical device manufacturer cases were developed using a 
combination of techniques.  This study is limited to device manufacturers as they are 
the responsible party for executing human factors studies.  These included exploring 
the company background to determine the number of employees, product portfolio 
and regulatory classification of the devices.  In addition, the profile of the participant 
was reviewed via social media on professional web sites such as LinkedIn.  Criteria for 
case study development included the type of device, the user, the size of company, 
the location and use of industrial design.  Semi-structured interviews were conducted, 
with 13 being undertaken at the participant’s place of work and five by Skype.  The 
interviews were conducted using an interview guide approach (Bauer 1996; Kvale and 
Brinkmann 2009) and lasted approximately one hour.  In order to assess each 
manufacturers opinions regarding user centered design and human factors, questions 
were directed at opening conversations on five distinct areas of: development 
process or approach to design; challenges of engaging users; methods; frequency of 
engaging users; and the influence of industrial design in regards to the process.  The 
interview questions consisted of the following: 
 
1. What is the development process/theoretical approach to design?  (Probe 
for user-centred design, participatory design, collaborative design, 
evidence of human factors process) 
2. What are the challenges in involving users within your design process? 
(Probe for specific tools, activities, requirements such as IEC 62366 that 
drive user involvement) 
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3. How often/where does the engineering/design team engage with users?  
(Probe for process of engagement, human factors study execution)  
4. Do you have industrial design (ID) within your organization? (Probe for the 
hiring of consultants: ID or human factors and responsibilities) 
 
These areas were selected as being the most important in order to meet the research 
objectives as all questions revolve around user input into the design process and all 
are required to meet agency requirements.   At the conclusion of the interview, 
specific artifacts, such as corporate guidance on design approach/design process 
training material or interesting artifacts discovered in the interview, were requested in 
order to provide further understanding and enable data analysis using a meta matrix 
display.  
 
Figure 2 illustrates the collective background on each manufacturer.  This figure 
describes the range in the types of users, with 3 companies developing two different 
types of devices; 9 companies with multiple types of users; and including the size, 
location and presence of industrial design illustrated for all companies. 
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Figure 2. Graphic details of participating manufacturers 
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With permission from the interviewees, all interviews were recorded using a 
Livescribe pen for reference and analysis that complied with ethical procedures of the 
University of Cincinnati.  Due to manufacturer confidentiality, no images were taken. 
 
Medical Device Industry (MDI) manufacturers included interviewees from 13 USA, 
three EU and two contract manufacturers. Examples of the types of the manufactured 
devices included laparoscopic surgical devices, orthopedic implants, assistive surgical 
technologies, endovascular devices, neurovascular devices, critical care devices, 
cardiac assistive technologies, neurologic diagnostic devices and general hospital 
equipment such as patient administered drug delivery devices.  Selected 
manufacturers included major medical device developers from each target area.  
Table 1 provides a summary of the size and location of the participating companies.   
Table 1. Medical device manufacturer participant breakdown 
Company Small < 50 Medium 51-150 Large >150 Total 
US Device Manufacturer 3 2 8 13 
EU Device Manufacturer 1 1 1 3 
US Contract Manufacturer  2  2  
All interviewees held leadership positions within their organization, therefore 
responsible for the design process and had an average of 12 years of experience. 
Table 2 describes the participating disciplines and leadership levels.  Interviewees 
were selected based on their leadership within the organization. 
 
Table 2. Interviewees by discipline 
Discipline Manager Director Vice President Chief Technical Officer 
Engineering 2 4 2 3 
Industrial Design 3 2  1 
Human Factors   1   
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Qualitative samples tend to be purposive rather than random (Miles et al. 2013).  As 
such, the selected manufacturers had to meet the following requirements (Table 3): 
 
• Type of device - Must manufacture at least one Class II device, which is a 
regulatory device classification and used in/for the catheter lab (CATH), critical 
care (CRIT), drug deliver (DELIV), surgery (SURG) or general hospital (GEN) 
• User - Any user group was welcome, however, at least one use location must 
be in a hospital in order to bound the collected data.  User groups included 
physicians (DR), nurses (NRS), patients (PT), caregiver (CARE) and technologists 
(TECH). 
• Size of company - A mix of large (LG) medium (MED) or small (SM) was 
targeted 
• Location - Must be located in either the USA or EU 
• Industrial Design (ID) - Must be familiar with the use and value of industrial 
design 
 
Table 3 Participant summary indicating the device type, user group, size, location and presence of ID 
 
 
Cross-case synthesis can be conducted by treating each individual case as a separate 
study and then aggregating findings across a series of studies (Yin 2013).   As such, 
“analysis is likely to be easier and the findings likely to be more robust than having 
only a single case” (Yin, 2013 p. 164).  Cross-case data requires comparison via 
common codes, common displays of data segments and reporting formats for each 
case (Miles et al. 2013).  All codes, displays and reporting formats are data-
condensing for the purposes of distilling data sets into “workable, intellectual 
coherent units” (Miles et al. 2013 p. 136). 
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To identify overall similarities and differences between multiple cases, a card sorting 
technique was employed as these are widely used in knowledge acquisition (Rugg 
and McGeorge 2005). Card sorting also supports the goals of organizing information 
into a usable taxonomy, with consideration to differences between groups, initially as 
a whole and then as individuals (Bussolon 2009).  For this analysis, each card 
contained uniform information regarding the size, location, user and type of device, 
in-house industrial design, profession of interviewee and brief answers to the main 
study questions.   An individual card was written for each company and then 
organized based on responses. This comparison analysis enabled a broad overview of 
each topic.  Figure 3 highlights a card sorting analysis for design approach.   
 
 
Figure 3. Card Sorting Example 
Further, a data display is an organized visual containing a compressed assembly of 
information that allows conclusion drawing and action (Miles et al. 2013).  Further 
mapping and data visualisation were used to determine patterns across case studies.  
A matrix display refers to a display chart or table including the codes in order to 
organise a vast array of condensed material into an at-a glance format for reflection, 
verification and conclusion drawing (Miles et al. 2014).  In order to facilitate further 
data analysis, data visualisation charts were developed using individual case images 
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based on Figure 2.  An example chart can be seen in Figure 4.  The vertical axis 
communicates the total number of participants reporting a finding.  The horizontal 
axis represents various topics identified from the data.  By using individual company 
graphics that include the specific requirements, further analysis based on company 
attributes was enabled.  From this visualisation, the data was analysed in both the 
vertical and horizontal axes.  These charts were used for noting patterns, explanations, 
causal flows and propositions in order to draw conclusions.    
  
 
Figure 4. Data visualization example 
 
 
3 Results 
 
Each of the human factors standards required for agency review involves collaborative 
exchanges with users.  As such, the results are presented with regard to the means of 
user involvement; activities used promoting collaborative exchanges; and the challenges 
with user involvement.  
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3.1 Means of user involvement  
All manufacturers involved users in the design process. Table 4 indicates the type of 
user involvement as described by interviewees.  A total of 13 companies had users 
involved through fee-based consulting agreements with medical device professionals 
immersing themselves and observing the clinical environment.  These manufacturers 
had users involved in formal device studies, noting that this was an agency 
requirement prior to approval to market a device.   
 
Table 4. Typical user involvement in device development 
N= User Involvement Activities or requirements involving users  
13 Consultancy fee Only interact with users who are dedicated consultants 
13 Immersion & 
observation 
Activities by the product development team members to 
more fully understand context of use 
12 Formal device 
assessment 
Requirement for user involvement by regulating agencies  
7 Advisory group Group of users selected to provide guidance in device 
development 
7 Informal 
interactions 
Activities not formally related to device development but 
use to build working relationship 
6 Key opinion 
leaders (KOLs) 
Selected users who have influence on clinical practice, 
typically through publication and/or procedure 
development 
 
A total of 7 companies had clinical advisory groups or reported informal interactions 
with users.  Three of these Companies (16, 13, and 3) utilized both.  Uniquely, 
Company 3 involved users as advisory group members for informal interactions and 
as key opinion leaders.  Likewise, Companies 14 and 2 reported advisory group and 
key opinion leaders.  In these instances, there were individual contracts with 
physicians as they served in both capacities. 
 
 15 
Users frequently received a fee through direct consulting, honoraria or donation and, 
in contextual enquiry studies, this extended to the hospital or institute where they 
practiced.  The act of simply observing care or involving users resulted in financial 
expectations, especially for those practicing in larger hospitals.  In addition, larger 
organizations, such as Company 15, often used a third party recruiter to identify 
study participants, thereby further increasing the cost.  A mid-size or start-up device 
company (Company 17), although hesitant to compensate, they would only do so if 
resources were available and it was absolutely necessary.  In these instances, greater 
emphasis was placed on relationships with individuals.  All companies used formal 
non-disclosure and non-compete agreements as routine practice when collaborating 
with users. 
 
Front-end user studies, such as contextual enquiry, were conducted by two of the 
large manufacturers (Companies 3 and 9).  These were described as time intensive 
studies, tying use behaviors within the clinical workspace to specific device 
performance outcomes.   Industry participants described that the number of users or 
stakeholders involved in these studies had increased to include those who were 
considered ancillary users (those who prepared the device for use) and that these 
stakeholders had a voice in the purchase decision.  User participation often ceased 
(briefly) between a contextual inquiry study/unmet needs investigations and the 
development of intellectual property (Companies 3,6,7,10, 11, 14). 
 
Participants conducted formal device assessments, wherein users were brought to an 
external facility such as a hotel, to provide feedback on a device as required by IEC 
62366 (Companies 2, 3, 6, 11, 14, 16).  If users were patients themselves or the device 
was intended for home use, the evaluations were conducted through collaboration 
with clinical personnel in order to identify appropriate patients, with the patients 
themselves being asked to use the device under direct observation following a 
summative usability assessment protocol.  This was documented and placed in a 
human factors dossier for agency review.  These validation protocols followed a 
scripted research protocol. 
 
One large manufacturer had put together clinical advisory boards consisting of KOL’s, 
with formal consulting agreements (Company 14).  This advisory board was active in 
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assisting in directing the product development strategy as well as assisting in the 
development of key attributes that made the device more acceptable to those 
making purchase decisions.  All members of the board received a fee and were 
required to maintain a design notebook to record intellectual property.  They were 
made up of clinical members who were influential in their community and served to 
assist the design team.  The reviews by the advisory group were formal planned 
activities.  The opinions of the study participants were that these boards were “not 
reflective of the mass market, rather they were only the top 5% of the world” 
(Company 3).  It was noted that feedback from the advisory board was different than 
feedback gathered from formal human factors studies.   Additionally, this advisory 
group was known to “have many ideas however get upset and take it personally 
when negative feedback (regarding a concept) was delivered” (Company 1).  This 
indicates the formal studies were less bias. 
 
Select users were involved in the development process through formal device 
evaluations or as part of an advisory group, often being made up from key opinion 
leaders (KOL’s).  Those involved were generally selected based on their personality or 
achievements in research and potential influence over other practitioners.  One small 
manufacturer (Company 12) commented on collaborative relationships in which the 
lead clinical support was a member of the leadership team although they no longer 
practiced medicine.   As a result, further collaborations with practicing clinicians were 
routinely sought for feedback.    
 
Informally, the device industry was routinely exposed to clinical practice.  Unlike 
contextual inquiry studies, with a planned immersion and observation activities, this 
was often ad hoc and conducted alongside ‘voice of customer’ marketing research.  
There was a realization that just asking questions was not enough information to 
drive design criteria as there was a need to explore opportunities more fully and gain 
a deeper understanding of practice.  This was described as “leading to better 
questions and more defined user input” (Company 3).    During these interactions, 
notes were occasionally taken although there was a tendency by industry personnel 
to be present in the observation and then reflect on the visit when completed.  
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3.2 Activities promoting collaborative exchanges  
Device companies enabled the inclusion of users in the device development process 
through specific activities.  Following data reduction, four types of activities were 
identified (see Table 5).  A total of 17 companies engaged users in specific device 
studies or reviews, with 13 reporting the involvement of users in workshops or device 
related labs.  Eight reported the involvement of users in human factors evaluation, 
with five companies having in-house industrial design teams.  Four companies 
without industrial design capability were engaged in medical device design related 
conversations at scientific conferences.  Additionally, all of these companies engaged 
with physicians as users, with these including both of the catheter device 
manufacturers. 
 
Table 5. Activities promoting user involvement 
N= Activities promoting user involvement Specific interactions of the user with 
medical device development teams 
17 Device Study or Review: Informal 
discussion 
Conducting a discussion on design 
concepts (in office or lab) 
13 Workshops and labs  Conducting specific design events to 
promote user engagement 
8 Human factor evaluations: Formal study 
meeting IEC 62366-1 requirements 
Design attributes analyzed using 
formal study 
4 Scientific conferences Discussion and presentation during 
user focused meetings 
 
Device use was studied through ad hoc observations and contextual enquiry that was 
conducted before design control, thereby exploiting customer databases held by the 
manufacturer.  A multidisciplinary team was always involved in the study, with one 
company highlighting “the ability to organize the information into key insights that 
were actionable by design” (Company 7).  The impact of a formalized contextual 
enquiry program was recognized in one large organization by office conversations 
based on “what problems were we trying to solve, rather than what color or less 
important details” (Company 10).    Ad hoc observations were also used to assist in 
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“learning new techniques, relationship building or to explore for specific project 
exploration” (Company 2).  For these visits, only senior engineering and marketing 
personnel were typically involved in observations for mid-sized companies.  In 
contrast, large companies only observed care as part of a formal study.  A deficiency 
identified in this approach was “the reliance on individual note taking with no good 
way to sort relevancy” (Company 2).   
 
Workshops and labs were used to promote collaboration between device developers 
and users.  In these instances, specific time was set aside from clinical care 
responsibilities for the purpose of exploring a device concept, procedural training for 
design team members, or to serve as a prompt for device ideation. During labs, the 
clinical personnel acted as trainers for designers and engineers and walked through 
important details using demonstrative models such as an animal or cadaver.  This 
was identified as a costly approach but viewed as an important event for start-up 
organizations.  There was typically no formal protocol with regards to the 
information to be learned although there was a formal protocol submitted to animal 
protection agencies identifying the purpose and scope of the exploration.   This 
activity was surgical device manufacturers conducted approach.  The design and 
usability information gathered during these session were not recorded in a formal 
report rather gathered ad hoc and not entered into formal data management 
systems. 
 
Due to agency mandates, eight manufacturers mentioned human factors and/or 
usability assessments meeting the requirements of IEC 62366-1.  In these instances, a 
specific usability lab or facility was rented for device review.  In others, the use of 
rapid prototyping with low fidelity functionality was used to review a device concept, 
with Company 3 commenting:  “we were a company full of really smart people, who 
used to think it’s impossible that the user does not think like us, however with user 
testing, we’ve learned our assumptions can be completely wrong”.  One approach by 
a mid-size company was to produce a concept and then return back to the user to 
modifications and adjustment in order to meet their needs.  In this approach, only 
one variable was adjusted at a time.  The common opinion for device reviews was 
that “users get overwhelmed by too many choices” (Company 12).  As a result, users 
were provided with only 2 options before being asked to verbally choose a 
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preference.  Then they were asked to explain the pros/cons of their decision with 
each iteration of options becoming closer to the final design of the device.  In these 
tests, user preferences generally remained consistent however, the description of 
context and background as to reasoning was inconsistent thus resulting in challenges 
when interpreting the data. 
 
In-depth interviews were conducted at scientific meetings as a means of gathering 
opinion regarding challenges and trends in the market.  These were often lead by 
the company’s marketing team and did not acquire rich design information unless 
there was “someone on the team who knows how to ask the right questions and 
then translate it into design criteria” (Company 11).  There was, typically, no 
formalized method of synthesizing the data, with the team discussing issues and the 
making their “best guess” (Company 3).  For those not involved in formal contextual 
inquiry studies, this approach was the alternative and described as “we do free flow 
conversations with users taking a spark of an idea and letting the tangencies of the 
conversation flow.”  In three instances, there was follow-up with users via email for 
the purpose of new device design rather than to further evaluate specific design 
concepts.   For home health devices, users were provided with diaries with a request 
to record “how they felt at a particular moment during device use” (Company 15).  
These diaries were used as interview memory prompts in order for the user to recall 
and justify their opinion. 
 
3.3 Challenges with user involvement  
The opinion of device manufacturers included specific reference to positive 
interactions with users when they were engaged in device development.  This was 
largely attributed to the fact that, in the visits to hospitals or care centers by product 
development professionals, there was an exchange of information but no selling.  
While this was seen as being positive, negative attributes arising from collaboration 
with users were identified.  Table 6 describes specific challenges as described by 
study interviewees. 
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Table 6. Industry challenges with user involvement 
N= Challenges to user 
involvement 
Hindrances of the development team which prevent 
user collaboration  
11 Lack of user knowledge 
of product development 
Users level of understanding in product 
development practices 
10 Access Making the connections and approvals for a 
meeting with users 
10 User expectations Un-communicated requirements by the user which 
negatively impact the relationship or unrealistic 
expectations as to what was possible by design 
7 Scheduling with users Coordinating calendars and variability of clinical 
practice 
7 Attitude and ego Personality influences on collaboration and team 
dynamics 
6 Conflicting user opinions Sense making with opposing viewpoints 
5 Cost of involving a user User compensation for involvement 
5 Healthcare law 
compliance 
Legal ramifications of laws resulted in a lack of 
desire to be involved with device companies 
2 IRB/ethic board 
requirements 
Requirements for user reviews such as contextual 
inquiry and formal usability studies, viewed as 
burdensome for development  
2 User creativity The extent to which a medical device user was able 
to envision an alternative clinical approach 
1 Translating what they say 
into device design 
information 
Systematic approach to analysis of data gathered 
from users by development teams. 
 
A total of 11 companies reported that the users’ lack of understanding of the 
product development process was a challenge.  Of the 11, 8 of these companies did 
not have in-house industrial design and involved all user groups.  The fact that users 
had limited knowledge of the product development process was identified as a 
significant burden and resulted in unclear communication with developers.  In one 
example, physician innovators with knowledge of the process were eager to have 
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their device on the market but did not have an appreciation of the amount of time 
required for development and testing.  Additionally, users could become impatient at 
the questioning by product development team members as they sought a 
fundamental understanding of the true clinical need as indicated by Company 13, 
“Medical device design teams spend considerable time understanding the clinical 
problem, target outcomes, and associated risks; whereas users have no idea if the 
device in question was in what stage in the development process” (Company 13).  
   
Gaining access to clinical care was a challenge for all user types and reported by 10 
manufacturers. Members of a development team could not simply schedule an 
appointment with a user and complete an observation without having to go through 
a process of preparation and planning.  As a general rule, special training and 
credentials must be submitted to a hospital well ahead of a visit.  Simple shadowing, 
which largely went undetected prior to the introduction of patient privacy laws, were 
halted by hospital administration if not planned in an appropriate manner.  For large 
companies (Company 14, 10, 6, 5, 3), this almost always involved an additional 
network and contact with a sales manager or representative and there was an 
unwritten rule that an engineer was never allowed to have interaction with a user 
without prior approval and acknowledgement by the sales team.  Smaller companies 
(N= 4) relied on personal relationships and repeated visits within the same institution 
in order to gain trust.  For device evaluations, device companies used a recruiter to 
avoid interruption with the sales relationships and to maintain blinded studies.  In 
two companies there was a trend in the device industry to only send more senior 
engineers for specific observations, leaving junior team members to learn about 
clinical practice through online videos and, in a few instances, specific engineering 
training labs. 
 
A total of 10 manufacturers reported that users had expectations of rights to a share 
of the intellectual property (IP).  Communicating that IP had already been filed 
became a balance in the conversation, potentially causing a rift in the collaborative 
relationship. Companies described an expectation of users to evaluate more 
developed and robustly designed prototypes.  As a result, this could lead to delays in 
gathering feedback and a desire to demonstrate lower fidelity prototypes for 
evaluation (Company 14).  There was an attitude that users struggled to provide true 
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and valuable feedback when presented with relatively simple concept sketches.  The 
challenge for the manufacturer was to measure the right goal with the right stimuli.  
In one instance, this meant that the manufacturer would “not always need users, 
(they) can do a heuristic analysis prior to involving users to gain insights in possible 
design changes” (Company 7).   
 
Scheduling time with users was described as “difficult and frustrating” (Company 14). 
Company 9 communicated that the cadence of medical device development progress 
did not necessarily match the clinical calendar.  Further, that “Hospitals and 
physicians were slow to respond and then it takes forever to explain our (industry) 
goals and be approved to interact.”  Once approved, challenges of scheduling were 
still problematic with regards to matching the needs of device development.  
 
Once a meeting was scheduled further challenges existed, such as what questions to 
ask and how to analyze the information.  This is evident in the quote by Company 3, 
“it was difficult knowing when and what to listen to in order to translate the 
information into design criteria…to know we’ve asked the right questions to the right 
people as we (industry) rarely have the opportunity to validate the information (with 
users)” (Company 3).    
 
Seven companies reported that the attitude and ego of the user could also be a 
hindrance to collaboration.  Each of these companies had physicians as users and 
only one of the companies (Company 17) had in-house industrial design.  The 
personalities of the difficult users were described as “not conducive to collaboration 
as they believe they sit at the right hand of god” (Company 16).  As a result, the 
management of social dynamics became increasingly important so as to not offend 
users and thereby hinder the collaborative process. In addition, companies described 
a reluctance to change and the slow adoption of new technologies within the 
practice of medicine.  Company 13 approached this problem with iterative changes 
rather than radical disruptions.  
 
Device industry development teams were concerned with the ownership of 
intellectual property and, as a result, rarely undertook brainstorm activity with users.  
Company 11 commented that users struggled to think of alternative means of clinical 
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practice and that, “they (users) were not good at it (brainstorming) and have a 
difficult time thinking of alternative ways of doing their job” (Company 11).  Several 
industry participants described users as having a “lack of mechanical aptitude” and a 
requirement to “design for the least intelligent person” (Company 4, 11, 14).   
 
Six Companies reported that the conflicting opinions of users were a challenge for 
design.  Typically, “the marketing group suggests, the more (users) the merrier in 
opinion, however different opinions that contradict each other become difficult to 
decipher in device design” (Company 12).  Selecting the right number of users 
becomes a challenge for the device industry as “users may reveal something that was 
never a requirement and then the design needs to change to accommodate desires.  
This was after we’ve started our design control process” (Company 12). 
 
There was a cost associated with involving users and the “activity was not cheap” 
(Company 18).  Sometimes the compensation went into education funds so as to 
avoid official reporting. In other instances, an official honorarium was required and 
expected.  It was apparent that users did not review or interact with industry 
professionals without expectation of reward.  The financial burden did “impact the 
ability to gather a wide opinion and making decisions on limited information, can 
make for bad decisions” (Company 12).  In order to contain costs, the overall number 
of study participants, their backgrounds, corporate user compensation norms and the 
number of study locations were explored and balanced.  
 
The management and requirements of healthcare laws (N=5) and IRB (N=2) 
reporting were viewed as a challenge for companies to engage the user.  Healthcare 
laws, such as the Sunshine Act in the US, require the reporting of any compensation 
for physicians that resulted in physician hesitancy due to conflict of interest. To avoid 
conflict of interest issues, users were often engaged in “preceptorship roles wherein 
they were paid to train product development personnel in the procedure during 
observations” (Company 2).  This enabled the device community to observe but 
always required a formal agreement, documentation and compensation.  Company 
18 commented that if additional approval such as IRB review was necessary, an 
additional three months might be required in order to run a device study.  As a 
result, this situation was avoided. IRB requirements were viewed as burdensome for 
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smaller organizations with limited budgets and tight timelines.   There was confusion 
amongst the study participants in regards to the need for IRB oversight for human 
factors studies.  This was determined by the individual study requirements e.g. direct 
patient interaction always required IRB approval.  The submission and management 
of IRB approval was placed on the usability study team with support from the 
product development team.  Additional budget in time and money was required for 
studies incorporating IRB approval.  
4 Discussion 
 
As the literature review highlights, the application of human factors standards within the 
medical device design process is an expectation according to both the FDA and MHRA. 
(FDA 2016; MHRA 2016).  Barriers in communication regarding human factors 
processes have been identified (Vincent et al. 2014) and the user was defined to vary 
dependent upon the device and can include a provider, patient, parent or caregiver 
(Money et al. 2011).  The literature provides background on specific human factors 
process requirements however does not include analysis in the implementation of these 
processes. 
 
Using a multiple case study design, this research enabled depth into the processes and 
attitudes in meeting the human factors standards as well as overall collaboration with 
users.  The participants selected were those responsible for the overall design process, 
direction and activities of the design team.  Their acknowledgement of human factors 
standards demonstrates the effectiveness of agency requirements.  
 
This paper has explored current practices within the medical device industry for the 
purposes of improving device design; applying human factors principles, the 
influences of regulatory bodies and interaction with users.  The results confirm that 
all medical device development activities begin with both the clinical problem and 
interactions with the user. This verifies the impact of regulatory standards to promote 
user-centered design and that interaction was welcomed but difficult for medical 
device companies to implement.  Through agency mandates, there were specific 
activities and methods that promoted user involvement.   However, based on the 
perceptions in the industry, users were not always as helpful nor were they 
necessarily easy to work with.   
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This research indicates a total of four specific issues between device users and 
industry in regards to the application of human factors standards.  This includes the 
following:  
 
1. Recognition of agency mandates required involvement of the user but access 
to users remained difficult. 
2. Users drove the approach to design but were perceived to lack understanding 
of their impact and the development process. 
3. Device evaluations, workshops/labs were activities promoting user 
involvement and were conducted under formal circumstances, with contract 
formalities that met a requirement rather than a casual exchange with 
frequent exchanges.  
4. Users expected compensation to collaborate with the device industry and 
their attitudes could negatively impact the application of human factors 
processes. 
5 Conclusion 
 
The barriers presented in this research have the potential to be resolved but only 
with greater commitment by both users and device developers.  As a result, 
alternative practices that may further promote collaborative device development can 
be recommended.  These include the following: 
 
• To enable access to users and connecting interested users with device 
developers, targeted social media may serve as a direct connection. 
• To ensure that users are familiar with the latest practices, developers should 
consider rotating device users (physicians/nurses/techs) as device 
development team members with limited time away from practice. 
• To more effectively collaborate with users, educational programs could be 
produced to acquaint users with the product development practice. 
• To ensure users understand their impact on device development, the 
contribution and limitations of user input could be more clearly defined at the 
beginning of all activities related to device development. 
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• To ensure consistent user input throughout the development process, a tool 
or means of verifying user criteria continuously in the design process beyond 
formal testing of prototypes could be employed.   
• To identify the most appropriate user for collaboration, a system could be 
developed as a means of filtering/directing users with particular personality 
traits that would be most effective at various stages in device development. 
 
The application of human factors standards and the practice of user-centered design 
remain a priority in the industry for the development of safe, effective and usable devices.  
Despite, challenges, it is clear that the industry respects these regulatory requirements 
and values the input of device users.   
6 Acknowledgements 
 
This research was the result of collaborations between Loughborough University Design 
School and the University of Cincinnati’s Medical Device Innovation & Entrepreneurship 
Program.  It would not have been possible without the cooperation and volunteer time of 
those medical device manufacturers included in this research.  We are grateful and 
appreciative of their insights and willingness to participate. 
 
This research did not receive any specific grant from funding agencies in the public, 
commercial or not-for-profit sectors. 
7 References 
 
 
Association for the Advancement of Medical Instrumentation (AAMI, 2013. A roundtable 
discussion: understanding medical devices and users in context. Biomed Instrum 
Technol., Fall, pp.8–13. 
de Ana, F.J. et al., 2013. Value driven innovation in medical device design: a process for 
balancing stakeholder voices. Annals of biomedical engineering, 41, pp.1811–21. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/23483372. 
Battarbee, K. & Koshinen, I., 2005. Co-Experience: User experience as interaction. 
CoDesign; International Journal of CoCreation in Design and the Arts, 1(1), p.18. 
Bauer, M., 1996. The narrative interview: Comments on a technique for qualitative data 
collection, Available at: http://opensigle.inist.fr/handle/10068/537304. 
Binder, T., Brandt, E. & Gregory, J., 2008. Editorial, Design Participation(-s). CoDesign; 
International Journal of CoCreation in Design and the Arts, 4(1), pp.1–3. 
Bussolon, S., 2009. Card sorting, category validity, and contextual navigation. Journal of 
Information Architecture, 1(2), pp.5–29. Available at: 
http://journalofia.org/volume1/issue2/02-bussolon/jofia-0102-02-bussolon.pdf. 
Cafazzo, J.A. & St-Cyr, O., 2012. From discovery to design: the evolution of human 
factors in healthcare. Healthcare quarterly (Toronto, Ont.), 15 Spec No, pp.24–29. 
Crisp, S., 1996. The medical device directives and their impact on the development and 
manufacturing of medical implants. Proceedings of the Institution of Mechanical 
 27 
Engineers.Part H, Journal of engineering in medicine, 210(4), pp.233–239. 
Elf, M. et al., 2007. Using system dynamics for collaborative design: a case study. BMC 
Health Services Research, 7(1), pp.1–12. Available at: 
http://dx.doi.org/10.1186/1472-6963-7-123. 
Fairbanks, R.J. & Wears, R.L., 2008. Hazards with medical devices: the role of design. 
Annals of emergency medicine, 52, pp.519–521. 
FDA, 2011. Applying Human Factors and Usability Engineering to Optimize Medical 
Device Design, 
FDA CDRH, 1997. Guidance Documents (Medical Devices and Radiation-Emitting 
Products) - Design Control Guidance For Medical Device Manufacturers, USA: 
Center for Devices and Radiological Health. Available at: 
http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocumen
ts/ucm070627.htm [Accessed February 1, 2015]. 
Gilman, B.L., Brewer, J.E. & Kroll, M.W., 2009. Medical device design process. 
Conference proceedings : ... Annual International Conference of the IEEE 
Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and 
Biology Society. Conference, 2009, pp.5609–5612. 
Grocott, P., Weir, H. & Ram, M.B., 2007. A model of user engagement in medical device 
development. International journal of health care quality assurance, 20(6), pp.484–
493. 
Justiniano, J. & Gopalaswamy, V., 2003. Practical Design Control implementation for 
Medical Devices, Boca Raton, Florida 33431: Interpharm CRC. 
Kvale, S. & Brinkmann, S., 2009. InterViews: learning the craft of qualitative research 
interviewing, Los Angeles: Sage Publications.  
Lin, L., Vicente, K.J. & Doyle, D.J., 2001. Patient safety, potential adverse drug events, 
and medical device design: a human factors engineering approach. Journal of 
Biomedical Informatics, 34(4), pp.274–284. 
Martin, J.L. & Barnett, J., 2012. Integrating the results of user research into medical 
device development: insights from a case study. BMC medical informatics and 
decision making, 12, p.74. 
Medina, L.A., Kremer, G.E.O. & Wysk, R.A., 2012. Supporting medical device 
development: a standard product design process model. Journal of Engineering 
Design, pp.1–37. 
MHRA, 2016. Human Factors and Usability Engineering – Guidance for Medical Devices 
Including Drug-device Combination Products, Available at: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/5284
95/MHRA_Human_factors_draft_guidance_June_2016.pdf  
Miles, M.B., Huberman, A.M. & Saldana, J., 2014. Qualitative Data Analysis, United 
States of America: Sage. 
Miles, M.B., Huberman, A.M. & Saldaña, J., 2013. Qualitative Data Analysis: A Methods 
Sourcebook, SAGE Publications. Available at: 
https://books.google.com/books?id=3CNrUbTu6CsC&pgis=1 [Accessed March 1, 
2015]. 
Money, A.G. et al., 2011. The role of the user within the medical device design and 
development process: medical device manufacturers’ perspectives. BMC medical 
informatics and decision making, 11, p.15. 
Ogrodnick, P., 2013. Medical Device Design: Innovation from Concept to Market, 
London: Elsevier Inc. 
Ogrodnik, P., 2013. Medical Device Design: Innovation from Concept to Market, London: 
Elsevier. 
Panescu, D., 2009. Medical device development. In Conference proceedings : Annual 
 28 
International Conference of the IEEE Engineering in Medicine and Biology Society. 
IEEE Engineering in Medicine and Biology Society. Annual Conference. pp. 5591–4. 
Rugg, G. & McGeorge, P., 2005. The sorting techniques: A tutorial paper on card sorts, 
picture sorts and item sorts. Expert Systems, 22(3), pp.94–107. 
Sanders, E.B.-N., 2002. From user-centered to participatory design approaches. Design 
and the social sciences: Making connections, pp.1–8. 
Taylor, P., Furniss, D. & Blandford, A., 2007. Understanding emergency medical 
dispatch in terms of distributed cognition : a case study Understanding emergency 
medical dispatch in terms of distributed cognition : a case study. , (July 2014), 
pp.37–41. 
Vincent, C.J., Li, Y. & Blandford, A., 2014. Integration of human factors and ergonomics 
during medical device design and development: It’s all about communication. 
Applied Ergonomics, 45(3), pp.413–419. Available at: 
http://www.sciencedirect.com/science/article/pii/S0003687013001208. 
Whitmore, E., 2004. Development of FDA-Regulated Medical Devices Prescription 
Drugs, Biologics and Medical Devices, Milwaukee, Wisconsin: American Society for 
Quality, Quality Press. 
Wiklund, M.E. & Wilcox, S.B., 2005. Designing usability into medical products, Boca 
Raton, Fla: CRC Press. Available at: 
http://uc.summon.serialssolutions.com/link/0/eLvHCXMwY2BQMEg2TwLWuqZpFm
aWackmwArSKBmo0DQFWPUmGhqnolzlg1SauwkxMKXmiTJIu7mGOHvolibHQ4c
w4pOMzcEzYhWGYgy8iaCl33kl4C1iKeIMrGnAeEoVB5Wd4kBzxBk4IiyNgvwiLAMg
XCEYV68YvI9Jr7BEHFhUg6NZ11DPFABvESsG. 
Yin, R.K., 2013. Case Study Research: Design and Methods 5th ed., SAGE Publications. 
Available at: https://books.google.com/books?id=OgyqBAAAQBAJ&pgis=1 
[Accessed March 1, 2015]. 
Zenios, S., Makower, J. & Yock, P., 2010. Biodesign: the process of innovating medical 
technologies, Cambridge University Press. 
 
 
 
 
